Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.

Diabetes Research and Clinical Practice
Luis E Simental-MendíaMario Simental-Mendía

Abstract

Previous studies have found reduced concentrations of both leptin and resistin after glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment; however, the evidence in this field is inconclusive. Therefore, the aim of this meta-analysis of randomized controlled trials was to evaluate the effect of GLP-1 RA on both leptin and resistin levels. The present systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on leptin and resistin concentrations. For this, PubMed-MEDLINE, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched. A random-effects model and a sensitivity analysis were performed for meta-analysis. Meta-analysis of 13 randomized controlled trials comprising 1,025 subjects indicated that administration of GLP-1 RA significantly decreases leptin (WMD: -4.85 ng/mL, 95% CI: -9.32, -0.38, p = 0.03) and resistin (WMD: -1.40 ng/mL, 95% CI: -2.78, -0.01, p = 0.05) serum levels. However, the effect size was sensitive to four studies for both leptin and resistin concentrations. The results of this meta-analysis of randomized controlled trials suggest that GLP-1 RA therapy reduces both leptin and resistin levels.

References

Feb 24, 2001·Nature·C M SteppanM A Lazar
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Peter F BodaryDaniel T Eitzman
Apr 6, 2002·Archives of Physiology and Biochemistry·G N ChaldakovL Aloe
Oct 9, 2002·Circulation·John P Cooke, Roberta K Oka
Apr 21, 2005·BMC Medical Research Methodology·Stela Pudar HozoIztok Hozo
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Feb 16, 2010·Diabetes Technology & Therapeutics·G DerosaA F G Cicero
May 7, 2011·British Journal of Pharmacology·Md S JamaluddinChangyi Chen
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Oct 8, 2014·International Journal of Obesity : Journal of the International Association for the Study of Obesity·E W IepsenS S Torekov
Mar 25, 2015·Journal of Diabetes Investigation·Yumie TakeshitaUNKNOWN Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group
Sep 4, 2015·American Journal of Physiology. Endocrinology and Metabolism·Amaia RodriguezGema Frühbeck
Sep 24, 2015·Journal of Hepatology·Matthew J ArmstrongJeremy W Tomlinson
Jul 7, 2017·Diabetes, Obesity & Metabolism·Signe FrøssingJens Faber
Jul 12, 2018·European Journal of Clinical Investigation·Xabier UnamunoVictoria Catalán
Oct 6, 2018·Nature Reviews. Cardiology·Evangelos K Oikonomou, Charalambos Antoniades
Nov 7, 2019·Nutrients·Manuel F LandechoGema Frühbeck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.